This report summarises key supply chain events and their expected impact on life science prices over the period September-October 2024. Existing geopolitical tensions and fluctuating commodity stocks are expected to drive global market volatility and supply chain disruptions Contract Development
Cytiva, a global life sciences company, has announced a collaboration with Pear Bio, a company pioneering personalized cancer treatments. This partnership aims to advance cancer research by improving tumor cell analysis through the use of Cytiva’s Via Extractor technology. The
Evonik has announced the expansion of its EUDRACAP portfolio with the introduction of a new functional capsule designed to deliver sensitive active ingredients, such as live biotherapeutic products (LBPs), to the ileo-colonic region. The new capsule, EUDRACAP colon, aims to
Cryoport, Inc. and SK pharmteco have entered a strategic collaboration to provide integrated logistics and manufacturing services to biotechnology and pharmaceutical companies. This partnership combines Cryoport’s expertise in supply chain solutions with SK pharmteco’s contract manufacturing capabilities, creating a streamlined
BioCina Pty Ltd., a global biologics Contract Development and Manufacturing Organization (CDMO), has announced a partnership with drug developer EnGeneIC Pty Ltd. This collaboration focuses on the technology transfer, process scale-up, and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream
Ascend Advanced Therapies has announced a major investment to expand its global infrastructure, targeting growth in its Alachua, Florida, and Munich, Germany facilities. The expansions aim to meet increasing demand in the gene therapy sector. The Alachua facility is undergoing
Eurofins CDMO Alphora has announced plans to build a new biologics manufacturing facility in Mississauga, Ontario. The 50,000 sq ft GMP facility will produce monoclonal antibodies (mAbs) and protein therapies for clinical and commercial use. This development is part of
PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has announced plans to invest over $365 million in new and expanded facilities to support the packaging of drug-device combination products. The expansion focuses on advanced drug delivery systems,
TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to introduce CleanScribe™ RNA Polymerase. This novel enzyme reduces the formation of double-stranded RNA (dsRNA) by up to 85% during in vitro transcription (IVT) for mRNA production, a key
Lonza has entered into a long-term commercial supply agreement with Vertex for the production of CASGEVY (exagamglogene autotemcel), the first cell therapy based on CRISPR/Cas9 technology. The therapy is designed as a one-time treatment for patients with transfusion-dependent beta-thalassemia or
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
